Ivim Health

What Ivim Health does

Ivim Health is a privately held, physician-led direct-to-consumer telehealth company headquartered in Columbus, Ohio, operating nationwide through a membership-based virtual care model. Co-founded by Dr. Taylor Kantor, Anthony Kantor, and Kelly Kantor, the company delivers ongoing individualized care across three primary verticals: weight loss via compounded and branded GLP-1 medications (semaglutide and tirzepatide), women's hormone health (anchored by the proprietary HormoneIQ symptom-scoring tool and HypoSpray transdermal estradiol), and general wellness/longevity (NAD+, Sermorelin, B12, lipotropics, and a branded supplement line). As of mid-2026 the company reports having served more than 470,000 patients through approximately 100 board-certified providers, and has published two peer-reviewed retrospective observational studies in Obesity Pillars documenting clinical outcomes.

The platform architecture combines a telehealth consultation layer, AI-assisted clinical documentation and member-facing chat, and direct-to-patient medication fulfillment through compounding pharmacy partners, with all clinical decisions reviewed by licensed providers. The business model is subscription-driven: a $75/month membership covers unlimited provider visits, functional health coaching, and 20% off supplements, while GLP-1 program enrollment adds $74.99/month plus $75–$149/month in medication fees, and a corporate channel (Ivím at Work) distributes these services as employer-sponsored benefits. Multi-state professional corporation entities (CA, IL, KS, NJ, NY, NC) provide the regulatory scaffolding for cross-state telehealth prescribing.

Ivim monetizes through a blend of recurring membership fees, per-program medication surcharges, supplement e-commerce, and emerging peptide therapy revenue. Go-to-market is direct-to-consumer with content marketing, PR coverage in outlets including The New York Times, Forbes, TIME, CNN, and Men's Health, and SMS/email engagement. The company is self-funded by its founders with no disclosed institutional capital, and operates without an enterprise customer base, relying entirely on a long-tail consumer population for revenue concentration.

Name

Ivim Health

Legal name

Ivim Services LLC

Website

https://ivimhealth.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

101–250 employees

Short description

Ivim Health is a privately held, physician-led direct-to-consumer telehealth company offering membership-based weight loss via GLP-1 medications, women's hormone health with its proprietary HormoneIQ tool, and wellness programs to more than 470,000 patients nationwide through approximately 100 board-certified providers.

Ownership category

akta.pro rank

Product category

Telehealth Weight Management and Wellness

NAICS

Other Ambulatory Health Care Services (6219), Ambulatory Health Care Services (621)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)

akta.pro primary industry

Membership/Subscription Concierge Virtual Care (HLALAAAH)

akta.pro secondary industries

Prescription-Based Digital Clinics (Condition-Specific Rx Programs) (HLALAAAD), DTC Telehealth with Integrated Online Pharmacy (Cash-Pay/Subscription) (HLALAIAA)

Keywords

• Telehealth weight management
• GLP-1 medication programs
• Hormone replacement therapy
• Subscription wellness membership
• Physician-led virtual care

Headquarters

HQ city

Columbus

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Supply Chain, Marketing or Sales, Technology or R&D, Operations, Others

Revenue model

1. Membership Subscription: Monthly membership fee covering ongoing physician-led care, unlimited provider visits, functional health coaches, patient experience team, and 20% off supplements. $75/month with first month free.
2. Medication Program Fees: Additional charges for GLP-1 medications on top of membership. GLP-1 Individualized Dosing program charges $74.99 monthly program fee plus $75-$149 per month for medications.
3. Supplement Sales: Non-prescription dietary supplements, vitamins, and nutritional supplements sold through e-commerce platform with 20% discount for members.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Ivim Health operates a physician-led telehealth platform offering subscription-based membership ($75/month) for ongoing, individualized virtual care across weight loss, hormone health, and whole-body wellness. The company delivers care through board-certified providers supported by AI-powered clinical tools, prescribing and managing compounded GLP-1 medications (semaglutide, tirzepatide), hormone replacement therapy, peptide therapies, and an e-commerce supplement line. Medications and products are shipped directly to patients nationwide without physical clinical locations.

Product overview

Ivim Health is a physician-led virtual medical health company based in Columbus, Ohio, operating as a telehealth platform offering individualized health and wellness programs. The core offering is a membership-based care model ($75/month) providing ongoing physician-led support across weight loss, hormone health, and whole-body wellness. The main programs include the GLP-1 Individualized Dosing Program (compounded semaglutide and tirzepatide), the Women's Hormone Health Program (featuring HormoneIQ symptom scoring and HypoSpray estradiol), the Microdosing Program, and various supplement offerings (NAD+, Sermorelin, B12, Lipotropic, Collagen+, Renu/NMN, Protein Powder, Creatine). The company also offers a Corporate Program (Ivím at Work) and is developing Men's Hormone Health and Peptide Therapies. All programs emphasize individualized, ongoing care with unlimited provider visits rather than episodic prescriptions.

Differentiator

Problem solved

Functional benefit

Products and services

• Ivím Membership Ongoing, individualized physician-led care subscription at $75/month providing members unlimited provider visits, functional health coaching, a dedicated patient experience team, 20% off supplements, and same-day availability across all programs. First month free with Summer 2026 promotion.
• GLP-1 Individualized Dosing Program Physician-led telehealth program providing compounded semaglutide and tirzepatide for chronic weight management with weekly provider check-ins and personalized dose adjustments. Pricing is $74.99 monthly program fee plus $75-$149/month for medications. Indicated for adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities.
• Microdosing Program Weight loss program that uses microdosed GLP-1 medications for patients who may benefit from lower initial dosing as part of their individualized treatment plan, delivered through Ivím's physician-led telehealth platform.
• Women's Hormone Health Program Telehealth hormone replacement therapy program for women experiencing perimenopause/menopause symptoms, including vasomotor symptoms, sleep and energy issues, mood changes, cognitive changes, sexual wellness concerns, and body composition changes. Uses the proprietary HormoneIQ™ symptom-scoring tool across six domains and the HypoSpray transdermal estradiol formulation.
• HormoneIQ™ Proprietary symptom-scoring assessment tool developed by Ivím's clinical team that scores patients across six domains (vasomotor symptoms, sleep and energy, mood, cognition, sexual wellness, and body composition) to guide individualized hormone therapy without requiring lab work as a prerequisite.
• HypoSpray Transdermal estradiol formulation designed to provide continuity for patients affected by a widening national estrogen patch shortage impacting major manufacturers including Amneal, Zydus, Sandoz, Noven, and Viatris.
• Compounded Semaglutide Compounded GLP-1 receptor agonist medication prepared by compounding pharmacies for chronic weight management, used with reduced-calorie diet and increased physical activity for adults with BMI ≥30 or BMI ≥27 with weight-related conditions. Not FDA-approved.
• Compounded Tirzepatide Compounded dual GLP-1 and GIP receptor agonist medication prepared by compounding pharmacies for chronic weight management, used with diet and exercise for adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities. Not FDA-approved.
• NAD+ Energy and metabolism supplement program offering NAD+ (Nicotinamide Adenine Dinucleotide) for cellular energy support, available in oral, sublingual, intranasal, and subcutaneous formulations.
• Sermorelin Peptide therapy for sleep and stress that may help increase muscle mass, energy, endurance, and provide anti-aging benefits. Self-administered as a sublingual medication taken nightly.
• B12 Vitamin B12 supplement for energy and metabolism support offered as part of Ivím's wellness supplement portfolio.
• Lipotropic Lipotropic supplement supporting energy and metabolism functions as part of Ivím's general wellness program.
• Ivím at Work Corporate Program Corporate wellness program offering employee access to Ivím's weight loss, hormone health, and wellness services as an employer-sponsored benefit for workplace populations.

Quantifiable outcome

• 99%+ of Ivim patients achieved clinically meaningful results (5%+ total body weight loss) with ongoing membership care
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature2 records

Partnerships

One partnership is on record.

• Novo NordiskminorOthersIvim Health competes with Novo Nordisk's branded GLP-1 medications (Wegovy, Ozempic, Saxenda) by offering compounded alternatives. While not a formal partnership, Ivim's GLP-1 program offers these branded options alongside compounded formulations. Novo Nordisk is referenced in safety information and medication guidance.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Hims & Hers Health: Public telehealth company offering direct-to-consumer subscription-based virtual care across weight loss (GLP-1s), hormone health, and wellness. The closest comparable in model, customer base, and category overlap; cited in industry coverage as a direct competitor to Ivim in the cash-pay GLP-1 market.
• Ro: Direct-to-consumer telehealth platform providing virtual care and pharmacy fulfillment across weight management, men's and women's health, and wellness. Competes head-to-head with Ivim across multiple condition verticals and shares a cash-pay, membership-style model.
• Noom: Subscription-based weight management platform that has expanded into GLP-1 offerings with virtual provider support. Cited alongside Ivim as a cash-pay telehealth company targeting GLP-1 demand, with overlapping customer base in weight loss seekers.
• LifeMD: Telehealth company offering direct-to-patient virtual care, prescription medications, and weight management programs including GLP-1s. Highly comparable DTC subscription model serving similar cash-pay weight-loss and hormone-health patients.
• Found: Telehealth weight-care platform offering physician-led GLP-1 programs with subscription-based pricing. Targets the same cash-pay GLP-1 customer with similar individualization messaging, making it a direct specialty competitor.
• Calibrate: Metabolic health telehealth program combining clinician-supervised GLP-1 treatment with coaching. Directly comparable in the physician-led, individualized, membership-based weight loss category where Ivim competes.
• PlushCare: Virtual primary care and weight management provider offering online physician consultations and prescription services, including for weight loss. Operates in the same DTC telehealth category with a similar subscription/visit-based model.
• Eden (formerly known as Peter MD / Fountain TRT): Telehealth provider focused on hormone replacement therapy and men's health with subscription-based virtual care. Comparable in condition-specific, cash-pay, membership-driven telehealth delivery, especially relevant given Ivim's expansion into HRT and Men's Hormone Health.

Broad incumbents

• Teladoc Health: Large public telehealth incumbent offering virtual primary care, chronic condition management, and specialty visits. Overlaps with Ivim's virtual care and chronic-condition positioning but operates as a broader platform with employer and payer distribution.
• Amwell: Public telehealth infrastructure and care delivery company offering virtual visits across multiple specialties. Comparable as a broader virtual-care player but targets enterprise/payer channels rather than Ivim's direct-to-consumer cash-pay model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/ivimhealth

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ivim Health